SV2A PET Imaging in Human Neurodegenerative Diseases [PDF]
Frontiers in Aging NeuroscienceThis manuscript presents a thorough review of synaptic vesicle glycoprotein 2A (SV2A) as a biomarker for synaptic integrity using Positron Emission Tomography (PET) in neurodegenerative diseases.
Lea Tenenholz Grinberg
exaly +8 more sources
Connectivity Mapping Using a Novel sv2a Loss-of-Function Zebrafish Epilepsy Model as a Powerful Strategy for Anti-Epileptic Drug Discovery [PDF]
Frontiers in Molecular Neuroscience, 2022 Synaptic vesicle glycoprotein 2A (SV2A) regulates action potential-dependent neurotransmitter release and is commonly known as the primary binding site of an approved anti-epileptic drug, levetiracetam.
Rafal M Kaminski +2 more
exaly +5 more sources
Development and Validation of a New Mouse Model to Investigate the Role of SV2A in Epilepsy. [PDF]
PLoS ONE, 2016 SV2A is a glycoprotein present in the membranes of most synaptic vesicles. Although it has been highly conserved throughout evolution, its physiological role remains largely unknown.
Catherine Menten-Dedoyart +9 more
doaj +8 more sources
Epilepsy and Behavior Reports, 2021 SV2A encodes a neuronal synaptic vesicle glycoprotein essential for neurotransmitter release. Altered SV2A function leads to epilepsy in animal models, yet only two reports of human variants have linked SV2A to syndromic drug-resistant epileptic ...
Daniel G Calame, Isabella Herman
exaly +3 more sources
Botulinum Neurotoxin-A Inhibits Tumor Growth in a Triple-Negative Breast Cancer Preclinical Model [PDF]
ToxinsTriple-negative breast cancer (TNBC) continues to be a medical challenge requiring multiple treatment options. SV2A, a protein involved in vesicular release, has emerged as a promising biomarker for various cancers.
Evoli N. Lopez +11 more
doaj +2 more sources
Fully Automated Azeotropic Drying-Free Synthesis of [18F]SynVesT-1 via Copper-Mediated Fluorination Using the Trasis All-in-One Module [PDF]
MoleculesSynaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane protein expressed in presynaptic vesicles. Positron emission tomography (PET) imaging of SV2A provides an in vivo measure of synaptic density and has broad applications in the study of ...
Falguni Basuli +3 more
doaj +2 more sources
Structural pharmacology of SV2A reveals an allosteric modulation mechanism in the major facilitator superfamily [PDF]
Nature CommunicationsThe synaptic vesicle glycoprotein 2A (SV2A), a member of the major facilitator superfamily (MFS), is a key target for antiseizure medications and a biomarker for synaptic density imaging.
Shabareesh Pidathala +7 more
doaj +2 more sources
Automated GMP production and long-term experience in radiosynthesis of the SV2A tracer [11C]UCB-J [PDF]
EJNMMI Radiopharmacy and ChemistryBackground Positron emission tomography (PET) is a non-invasive imaging technique that enables the quantification of specific biological and pharmacological processes in vivo.
Saara Wahlroos +5 more
doaj +2 more sources
Synaptic Vesicle Glycoprotein 2A: Features and Functions
Frontiers in Neuroscience, 2022 In recent years, the field of neuroimaging dramatically moved forward by means of the expeditious development of specific radioligands of novel targets.
Rachele Rossi +9 more
doaj +1 more source
Brain Sciences, 2021 Synaptic vesicle protein 2A (SV2A), the target of the antiepileptic drug levetiracetam (LEV), is expressed ubiquitously in all synaptic terminals. Its levels decrease in patients and animal models of epilepsy.
Itzel Jatziri Contreras-García +6 more
doaj +1 more source